Liver International

Article	Citations
Frequency of the PNPLA3 rs738409 polymorphism and other genetic loci for liver disease in a Guatemalan adult population	186
Navigating portal hypertension: Unlocking safe passage to healthy pregnancy in EHPVO	157
Long‐term outcomes after liver transplantation for ACLF – Don’t forget quality of life!	93
Author's reply: The relationship between systemic inflammation and liver fibrogenesis in patients with cirrhosis	92
Different methodologies of protein induced by vitamin K absence or antagonist II in patients without hepatocellular carcinoma	89
Letter to the Editor regarding “Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis”	81
MNS1 promotes hepatocarcinogenesis and metastasis via activating PI3K/AKT by translocating β‐catenin and predicts poor prognosis	79
Endogenous Sex Hormones and Significant Hepatic Fibrosis in US Adults	75
Liver Disease Complicating Familial Mediterranean Fever: A Study on 66 Patients Out of 533 Adult From the JIR Cohort	63
Liver Injury due to Intravenous Methylprednisolone in the Drug‐Induced Liver Injury Network	62
Acute and acute‐on‐chronic liver failure: Pathogenesis, management and perspectives	62
Genetic Variants of GBP4: Reduced Risks for Drug‐Induced Acute Liver Failure in Non‐Finnish European Population	61
The Potential and Challenges of Autophagy in the Treatment of Liver Fibrosis	61
No impact of COVID‐19 epidemic on decompensation of alcoholic liver disease: Results from a single centre in Milan	59
DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti‐DKK1 therapeutic DKN‐01	59
High disease burden and healthcare resource usage in patients with acute porphyria—A population‐based analysis	54
Intraindividual comparison of prognostic imaging features of HCCs between MRIs with extracellular and hepatobiliary contrast agents	53
AI‐based digital pathology provides newer insights into lifestyle intervention‐induced fibrosis regression in MASLD: An exploratory study	53
Cover Image	51
High end‐of‐treatment hepatitis B core‐related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy	51
Reply to: “Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank”	50
Issue Information	46
	45
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank	45
Effect of statins on the recurrence of hepatocellular carcinoma after liver transplantation: An illusion revealed by exposure density sampling	44

Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction‐associated fatty liver disease in Korea	43
	43
	42
Issue Information	41
Tolvaptan for difficult‐ to ‐treat ascites: Difficulties in opening doors for GWAS application	41
Is fresh frozen plasma transfusion associated with outcomes in acute variceal bleeding?	41
Issue Information	41
Improving the accuracy of outcome prediction for hepatocellular carcinoma: Asia strategies	40
How to get away with liver innate immunity? A viruses’ tale	39
MR elastography to predict haemodynamic response to beta‐blockers—The story is still incomplete	39
Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction‐associated steatotic liver disease?	38
Prognosis algorithms for acute decompensation of cirrhosis and ACLF	37
Improving prediction of hepatocellular carcinoma in chronic hepatitis B by machine learning: Productive relationship of medicine with computer science	37
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology	37
HBV cure—The light at the end of the tunnel?	37
	37
High prevalence of lower limb atherosclerosis is linked with the gut–liver axis in patients with primary biliary cholangitis	36
Thy‐1 restricts steatosis and liver fibrosis in steatotic liver disease	36
COVID‐19, adaptative immune response and metabolic‐associated liver disease	36
Vaccination against COVID‐19 decreases hospitalizations in patients with cirrhosis: Results from a nationwide analysis	36
Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma	36
Hepatitis delta virus infection in the Middle East	36
Enoxaparin attenuates pyrrolizidine alkaloids‐induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression	36
Organ‐specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study	35
Management of biliary tract cancers in early‐onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort	35
Exercise training improves serum biomarkers of liver fibroinflammation in patients with metabolic dysfunction‐associated steatohepatitis	34
Lower frequency of MDSCs was significantly related to functional cure in CHB patients treated with peginterferon	34
Response to overcoming the challenges in eliminating viral hepatitis in low‐ and middle‐income countries	33
Perilipin 5 protects the mitochondrial oxidative functions and improves the alcoholic liver injury in mice	32
Impact of socio‐economic environment on incidence of primary liver cancer in France between 2006 and 2016	32
Liver disease mortality and hospitalisations among people with type 2 diabetes mellitus: A population‐based study	32
Dual alcohol and metabolic‐related liver disease: Results from a population of liver transplant patients	32
Is ageing a problematic hurdle to the efficacy of first‐line atezolizumab plus bevacizumab in hepatocellular carcinoma?	31
From complement to complosome in non‐alcoholic fatty liver disease: When location matters	31
Von Willebrand factor as a predictor of mortality in acute‐on‐chronic liver failure: Do not throw out the baby with the bathwater	31
Causal effect of lower birthweight on non‐alcoholic fatty liver disease and mediating roles of insulin resistance and metabolites	31
Issue Information	31
von Willebrand factor does not predict short‐term mortality in ACLF	31
Inside Front Cover	30
Issue Cover	30
	30
Rare liver diseases are not rare in China	29
Issue Information	29
Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with protease inhibitors‐based direct‐acting antivirals?	29
Issue Information	28
A new diagnostic criterion for sarcopenia: The fallout of lack of consensus	28
Different minimal alcohol consumption in male and female individuals with metabolic dysfunction‐associated fatty liver disease	28
Comment on ‘Therapeutic plasma‐exchange improves systemic inflammation and survival in acute‐on‐chronic liver failure’	28
The evolving phenotype of autoimmune hepatitis across the millennium: The 40‐year experience of a referral centre in Italy	28
The use of APASL consensus for the diagnosis of hepatitis B virus‐related acute‐on‐chronic liver failure	28

Anti‐gp210 and other anti‐nuclear pore complex autoantibodies in primary biliary cholangitis: What we know and what we should know	27
COVID‐19 and the liver – Lessons learned	26
Incidence of liver‐related morbidity and mortality in a population cohort of non‐alcoholic fatty liver disease	26
Importance of gender differences in body composition for liver transplantation and the ‘Sarco‐Model’ study	26
Golexanolone improves fatigue, motor incoordination and gait and memory in rats with bile duct ligation	26
Screening and surveillance of oesophageal varices in patients with HCV‐positive liver cirrhosis successfully treated by direct‐acting antiviral agents	26
Predicting post‐resection early recurrence of hepatocellular carcinoma: Defining the role of microvascular invasion	26
m5C and m6A modification of long noncoding NKILA accelerates cholangiocarcinoma progression via the miR‐582‐3p‐YAP1 axis	26
	25
Changing epidemiological features of hepatocellular carcinoma: Taiwan's position	25
Double‐negative T cells regulate the progression of liver fibrosis through Th9 cells differentiation	25
Issue Information	25
Patient‐specific genetic factors predict treatment failure in sofosbuvir‐treated patients with chronic hepatitis C	25
	25
Treatment endpoints for chronic hepatitis D	24
Reply to Yao et al.	24
EpCam is required for maintaining the integrity of the biliary epithelium	24
Atezolizumab and bevacizumab for HCC in the real world	24
Cirrhotic cardiomyopathy prevalence according to the new criteria	24
	23
G‐CSF—In Patients With Severe Alcohol‐Associated Hepatitis: A Real‐World Experience	23
High histamine levels are associated with acute‐on‐chronic liver failure and liver‐related death in patients with advanced chronic liver disease	23
Dual‐aetiology MAFLD and metabolic dysfunction	23
Social work's role in severe depression of MASLD	23
Metabolic syndrome traits differentially and cumulatively influence micro‐ and macrovascular disease risk in patients with MASLD	23
Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort)	22
Validation of a novel point‐of‐care test for alanine aminotransferase measurement: A pilot cohort study	22
Elevated Porcupine Disrupts Lipid Metabolism and Promotes Inflammatory Response in MASLD	22
Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct‐acting antivirals	22
Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus	22
Analysis of factors associated with discrepancies between predicted and observed liver weight in liver transplantation	22
Prognosis of hospitalized patients with cirrhosis and acute kidney disease	22
Epidemiological projections of viral‐induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination	22
Response to “Predicting post‐resection early recurrence of hepatocellular carcinoma: Defining the role of microvascular invasion”	21
JAM‐A is a multifaceted regulator in hepatic fibrogenesis, supporting LSEC integrity and stellate cell quiescence	21
Prevalence and incidence of hepatitis C infection amongst men who have sex with men in a population‐based pre‐exposure prophylaxis program in British Columbia, Canada	21
Think twice about IgG4‐related diseases before operating on hepatic masses	21
Liver pathology and biochemistry in patients with mutations in TRIM37 gene (Mulibrey nanism)	21
Role of liver biopsy in the management of idiosyncratic DILI	21
Real‐world economic burden of hepatitis C and impact of direct‐acting antivirals in France: A nationwide claims data analysis	21
Identification and validation of microtubule depolymerizing agent, CYT997, as a potential drug candidate for hepatocellular carcinoma	21
Acute‐on‐chronic liver failure: Where do we stand?	21
An ultrasound image‐based deep multi‐scale texture network for liver fibrosis grading in patients with chronic HBV infection	21
Assessment of myocardial dysfunction in cirrhotic patients: Should we look at the left atrium rather than at the left ventricle?	21
Time since liver transplant and immunosuppression withdrawal outcomes: Systematic review and individual patient data meta‐analysis	21
Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa region	20
The pituitary tumour‐transforming gene 1/delta‐like homologue 1 pathway plays a key role in liver fibrogenesis	20
Plasma human neutrophil peptides as biomarkers of disease severity and mortality in patients with decompensated cirrhosis	20
Abnormal cholesterol metabolism underlies relative adrenal insufficiency in decompensated cirrhosis	20
Bringing evidence to the MAFLD‐MASLD debate	19
Is hepatitis delta underestimated?	19
The NAFLD‐MAFLD debate: Is there a Consensus‐on‐Consensus methodology?	19
Defining recompensation of alcohol‐related liver disease: A step beyond decompensated cirrhosis	19
Estimating the prevalence of hepatitis delta virus infection among adults in the United States: A meta‐analysis	19
EASL versus LI‐RADS: Intra‐individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC	19
Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients	19
Extrahepatic autoimmune diseases in autoimmune hepatitis: Effect on mortality	19
Limited efficacy of atezolizumab and bevacizumab for hepatocellular carcinoma previously treated with tyrosine kinase inhibitor	19
A novel serum metabolomic panel distinguishes IgG4‐related sclerosing cholangitis from primary sclerosing cholangitis	19
Measuring the impact of the updated Steatotic liver disease nomenclature and definition	18
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	18
An optimized short‐term steroid therapy for chronic drug‐induced liver injury: A prospective randomized clinical trial	18
Viral hepatitis C cascade of care: A population‐level comparison of immigrant and long‐term residents	18
Profiles of liver fibrosis evolution during long‐term tenofovir treatment in HIV‐positive patients coinfected with hepatitis B	18
Long‐term outcome of hepatitis delta in different regions world‐wide: Results of the Hepatitis Delta International Network	18
An oral phenylacrylic acid derivative suppressed hepatic stellate cell activation and ameliorated liver fibrosis by blocking TGF‐β1 signalling	18
Improving the hepatitis C virus care cascade with the in‐hospital Reflex tEsting ALarm‐C (REAL‐C) model	18
Serum keratin 19 (CYFRA21‐1) is a prognostic biomarker in severe alcoholic hepatitis	18
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib	18
Hepatocellular adenoma in men: Is it time for a precision approach?	18
A changing landscape of alcohol consumption in the women	18
Maternal and fetal outcomes of pregnancies complicated by acute hepatitis E and the impact of HIV status: A cross‐sectional study in Namibia	18
Inflammatory myofibroblastoma mimicking cavernous hemangioma in the liver	18
Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort	18
Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice	18
Hypertransaminasemia and liver fibrosis associated with haptoglobin retention and anhaptoglobinemia in a paediatric patient	18
Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis	18
Influence of NOD2 risk variants on hepatic encephalopathy and association with inflammation, bacterial translocation and immune activation	17
A multi‐site, nurse‐coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia	17
Artificial replication cohort: Leveraging AI‐fabricated data for genetic studies	17

Endogenous sex hormones and nonalcoholic fatty liver disease in US adults	17
Predicting hepatitis B e Antigen seroconversion after pregnancy—The SydPregScore	17
Moderation effect of economic status in the association between early life famine exposure and MAFLD in adulthood	17
Mycophenolate and SARS‐CoV‐2 vaccination: Mixing oil and water	17
MBOAT7 in liver and extrahepatic diseases	17
Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population‐based study	16
Differential fuel utilization in liver transplant recipients and its relationship with non‐alcoholic fatty liver disease	16
Is elimination of HCV in 2030 realistic in Central Europe	16
Utility of telemedicine in the treatment of patients with chronic HCV infection using DAAs in remote areas with limited resources	16
Alcohol‐related hepatocellular carcinoma is a heterogenous condition: Lessons from a latent class analysis	16
Migration rate using fully covered metal stent in anastomotic strictures after liver transplantation: Results from the BASALT study group	16
Elimination of HDV: Epidemiologic implications and public health perspectives	16
Racial differences in primary sclerosing cholangitis mortality is associated with community socioeconomic status	16
Pathological neutrophil migration predicts adverse outcomes in hospitalized patients with liver cirrhosis	16
Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?	16
Epidemiology and Risk Determinants of Drug‐Induced Liver Injury: Current Knowledge and Future Research Needs	15
Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non‐alcoholic fatty liver disease	15
Aurora kinase A regulates liver regeneration through macrophages polarization and Wnt/β‐catenin signalling	15
Serum concentration of taurochenodeoxycholic acid predicts clinically significant portal hypertension	15
Prognostic implications of CT/MRI LI‐RADS in hepatocellular carcinoma: State of the art and future directions	15
Letter to Editor: ‘Recompensation After TIPS Reduces the Incidence of Hepatocellular Carcinoma and Increases Survival in Patients With Cirrhosis’	15
Update on heme biosynthesis, tissue‐specific regulation, heme transport, relation to iron metabolism and cellular energy	15
Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT‐FOXO3 signalling pathway	15
Zonated iron deposition in the periportal zone of the liver is associated with selectively enhanced lipid synthesis	15
Autoimmune liver diseases and diabetes: A propensity score matched analysis and a proportional meta‐analysis	15
Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study	15
Novel Emerging Mechanisms in Acetaminophen (APAP) Hepatotoxicity	15
Clinical characteristics and prognosis of hospitalized patients with moderate alcohol‐associated hepatitis	15
Relative adrenal insufficiency in the non‐critically ill patient with cirrhosis: A systematic review and meta‐analysis	15
Impact of in vitro fertilization‐embryo transfer on mother‐to‐infant transmission in women with chronic HBV infection	15
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy	15
The risk of hepatitis C virus recurrence in hepatitis C virus‐infected patients treated with direct‐acting antivirals after achieving a sustained virological response: A comprehensive analysis	15
Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta‐analysis	15
Targeted HBx gene editing by CRISPR/Cas9 system effectively reduces epithelial to mesenchymal transition and HBV replication in hepatoma cells	14
Mycophenolate mofetil decreases humoral responses to three doses of SARS‐CoV‐2 vaccine in liver transplant recipients	14
Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta‐analysis: Focusing on the non‐overlap groups	14
Experimental liver models: From cell culture techniques to microfluidic organs‐on‐chip	14
Autoimmune hepatitis triggered by COVID‐19: A report of two cases	14
Associations between alcohol consumption and hepatic steatosis in the USA	14
Long‐term complications in acute porphyria	14
Metabolic Dysfunction‐Associated Steatotic Liver Disease Increases the Risk of Severe Infection: A Population‐Based Cohort Study	14
Age‐adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID‐19 patients	14
Serum‐free light chains as a dependable biomarker for stratifying patients with metabolic dysfunction‐associated steatotic liver disease	14
APASL‐ACLF Research Consortium–Artificial Intelligence (AARC‐AI) model precisely predicts outcomes in acute‐on‐chronic liver failure patients	14
Liver fibrosis phenotyping and severity scoring by quantitative image analysis of biopsy slides	14
Impact of Direct‐Acting Antiviral Therapy on All‐Cause Mortality in Chronic Hepatitis C Patients	14
Pharmaco‐Economic Assessment of Screening Strategies for High‐Risk MASLD in Primary Care	14
Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa	14
Trends in the inpatient burden of alcohol‐related liver disease among women hospitalized in the United States	14
The effect of biliary obstruction, biliary drainage and bile reinfusion on bile acid metabolism and gut microbiota in mice	14
Hepatic macrophages: Key players in the development and progression of liver fibrosis	14
Sex‐specific effects of PNPLA3 I148M	14
Association of Liver Disease and Chronic Pruritus: A Case–Control Study	14
Natural history, spectrum and outcome of stage 3 AKI in patients with acute‐on‐chronic liver failure	13
A history of variceal bleeding is associated with further bleeding under atezolizumab–bevacizumab in patients with HCC	13
Integrating PNPLA3 into clinical risk prediction	13
Impact of hepatitis D reflex testing on the future disease burden: A modelling analysis	13
Confirmation of guideline‐defined hepatitis C screening strategies within the ‘Check‐Up35+’ examination in the primary care setting	13
MYO5B‐associated diseases: Novel liver‐related variants and genotype‐phenotype correlation	13
A population‐based study of pyogenic liver abscess in Korea: Incidence, mortality and temporal trends during 2007‐2017	13
Inhibition of HSPA8 by rifampicin contributes to ferroptosis via enhancing autophagy	13
Machine learning in primary biliary cholangitis: A novel approach for risk stratification	13
Clinical impact of sexual dimorphism in non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH)	13
Seroprevalence of hepatitis C virus infection in children: A systematic review and meta‐analysis	13
High prevalence of porto‐sinusoidal vascular disease in patients with constantly elevated gamma‐glutamyl transferase levels	13
Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection	13
The relevance of the liver volume increase after ALPPS	13
Hepatocytic ballooning in non‐alcoholic steatohepatitis: Dilemmas and future directions	13
Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis	13
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort	13
Usefulness of PNPLA3 variant for predicting hepatic events in steatotic liver disease: a matter of ethnicity or baseline risk?	13
The crosstalk network of XIST/miR‐424‐5p/OGT mediates RAF1 glycosylation and participates in the progression of liver cancer	13
Impact of major depression and antidepressant use on alcoholic and non‐alcoholic fatty liver disease: A population‐based study	12
Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48	12
Diagnostic accuracy of fibrosis tests in children with non‐alcoholic fatty liver disease: A systematic review	12
Maternal high‐fat diet disrupted one‐carbon metabolism in offspring, contributing to nonalcoholic fatty liver disease	12
Long non‐coding RNA H19 as a biomarker for hepatocellular carcinoma	12
Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end‐stage renal disease on maintenance haemodialysis	12
Plastic compounds and liver diseases: Whether bisphenol A is the only culprit	12
In Response to the Letter to the Editor by Walia et al.RE: Kassa et al. 2024 ‘Prevalence, Trends, and Distribution of Hepatitis C Virus Among the General Population in Sub‐Saharan Africa: A	12
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis	12
Chronic hepatic involvement in the clinical spectrum of A20 haploinsufficiency	12
Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol‐related cirrhosis	12
Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements	12
The integrated stress response‐related expression of CHOP due to mitochondrial toxicity is a warning sign for DILI liability	12
Screening for hepatitis C at the time of the pandemic: Need to adjust the shot	12
Is elimination of HCV realistic by 2030: France	12
Rates of decompensation, hepatocellular carcinoma and mortality in AMA‐negative primary biliary cholangitis cirrhosis	12
Mechanisms of immunity in acutely decompensated cirrhosis and acute‐on‐chronic liver failure	12
Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis	12
MASLD, At‐Risk MASH and Increased Liver Stiffness Are Associated With Young Adulthood Obesity Without Residual Risk After Losing Obesity	11
Exosomal ETV4 Derived From M2 Macrophages Induces Growth, Glycolysis and Stemness in Hepatocellular Carcinoma by UpRegulating SULT2B1 Expression	11
Correction to ‘Development and Validation of an Image Biomarker to Identify Metabolic Dysfunction Associated Steatohepatitis: MR‐MASH Score’	11
Pharmaceutical industry payments and prescriptions of direct acting antiviral drugs for hepatitis C virus infection	11
Correction to “Erythropoietic protoporphyrias: Pathogenesis, diagnosis and management”	11